Dasatinib İlişkili Şilotoraks

Dasatinib is a potent second-generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The most common adverse event associated with dasatinib therapy is fluid retention, including pleural effusion. Dasatinib-related chylothorax has rarely been reported. The clinical manifestations, pathophysiology, management, and prognosis are not fully understood. Here we report a 40-year-old woman presenting with chylothorax following dasatinib use. We propose the hypothesis of its mechanism as well as offering a review of the relevant literature.

Özet

Özet: Dasatinib kronik miyeloid lösemi tedavisinde kullanılan etkin bir ikinci kuşak tirozin kinaz inhibitörüdür. Dasatinib tedavisi ile ilişkili en sık görülen yan etki plevral effüzyonu da içeren sıvı retansiyonudur. Dasatinib ile ilişkili şilotoraks nadiren bildirilmiştir. Klinik belirtileri, patofizyolojisi, yönetimi ve prognozu tam olarak anlaşılamamıştır. Burada dasatinib kullanımı sonrasında şilotoraks gelişimi ile başvuran 40 yaşında bir kadın sunulmuştur. Dasatinib ile ilişkili şilotoraks gelişiminin mekanizmasının yanı sıra, konu ile ilgili literatür derlemesinden de bahsedilmektedir.

🔖

Cite This Article

HUANG, Y., WANG, C., HUANG, J., YEH, K., LAİ, C., WU, T., CHANG, P., CHANG, Y., LAN, Y. (2015). Dasatinib İlişkili Şilotoraks. Turkish Journal of Hematology, Cilt: 32 - Sayı: 1, 68–72. https://ajindex.com/articles/412806

References (12)

.1. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Ipiña JJ, Kim DW, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C, Hochhaus A. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year followup from a randomized phase 3 trial (DASISION). Blood 2012
Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010
Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol 2010
Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972
Keam SJ. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. BioDrugs 2008
Abbott BL. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia. Clin Ther 2012
Bristol-Myers Squibb. Product Information: SPRYCEL(R) Oral Tablets, Dasatinib Oral Tablets. Princeton, NJ, USA, BristolMyers Squibb, 2010. 8. McGrath EE, Blades Z, Anderson PB. Chylothorax: aetiology, diagnosis and therapeutic options. Respir Med 2010
Doerr CH, Allen MS, Nichols FC 3rd, Ryu JH. Etiology of chylothorax in 203 patients. Mayo Clin Proc 2005
STI571 Prospective International Randomized Trial (SPIRIT 2). Available at http://www.spirit-cml.org/spirit-2-home.aspx
accessed 24 August 2012. 11.Doerr CH, Staats BA, Markovic SN. Chylothorax in chronic lymphocytic leukemia patient. Am J Hematol 2002
Scholz GA, Sirbu H, Semrau S, Anders K, Mackensen A, Spriewald BM. Persisting right-sided chylothorax in a patient with chronic lymphocytic leukemia: a case report. J Med Case Rep 2011
Thomas LC, Maida MJ, Martinez-Outschoorn U, Filick